Norway has just bought 11m doses of the$GlaxoSmithKline (GSK.US)$H5N1 vaccine.$Novavax (NVAX.US)$has already proven efficacy against H5N1, so they should mive fast to get orders in!
More on$Novavax (NVAX.US)$‘s new strategic outlook - looking positive with new popeline candidates (VZV one sounds interesting), and a very interesting mention of a pivot to using its Matrix-M adjuvent in oncology. Time to adjust the ratings I think! Novavax is Powering the Future of Vaccines Through R&D and Value-creating Business Strategy - Jan 13, 2025
已读乱回最厉害 : ur here again, how was ur curevac stock? k
Chen trader moo OP 已读乱回最厉害 : Just keep waiting, brother, hold on![joy 😂](https://static.moomoo.com/nnq/emoji/static/image/img-apple-64/1f602.png)
Chen trader moo OP 已读乱回最厉害 : Be patient, be patient.
已读乱回最厉害 Chen trader moo OP : hahahaha i sold at my cost and get back my money
Chen trader moo OP 已读乱回最厉害 : Not bad, recently returned to last year's new high.
View more comments...